Toward stratified treatments for bipolar disorders

European Neuropsychopharmacology

Volumn 25, Issue 3, 2015, Pages 283-294

  Hasler, Gregor ^a   Wolf, Andreas ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Bipolar disorder; Personalized medicine; Precision medicine; Stratified medicine; Treatment optimization

Indexed keywords

ASENAPINE; BIOLOGICAL MARKER; CARBAMAZEPINE; DOPAMINE; GLUTAMIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HLA B ANTIGEN; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OLANZAPINE; QUETIAPINE; SEROTONIN TRANSPORTER; TRIACYLGLYCEROL; VALPROIC ACID; ANTIDEPRESSANT AGENT;

AGITATION; ANTIDEPRESSANT ACTIVITY; BEHAVIOR CHANGE; BEHAVIORAL ECONOMICS; BIOLOGY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BRAIN SIZE; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; COGNITIVE THERAPY; CONCEPTUAL FRAMEWORK; DECISION MAKING; ENDOPHENOTYPE; EPIGENETICS; FACIAL EXPRESSION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GRAY MATTER; HEREDITY; HUMAN; IMMUNOLOGY; MAJOR DEPRESSION; MENTAL DISEASE; MOOD DISORDER; NERVE CELL PLASTICITY; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; POLYSOMNOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SKILL; SYMPTOM; THERAPY EFFECT; TREATMENT RESPONSE; PATHOPHYSIOLOGY;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; ENDOPHENOTYPES; HUMANS; NEUROIMAGING; NEUROPSYCHOLOGY;

EID: 84925965345     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.12.006     Document Type: Review

References (132)

1. Ahn K.H., Lyoo I.K., Lee H.K., Song I.C., Oh J.S., Hwang J., Kwon J., Kim M.J., Kim M., Renshaw P.F. White matter hyperintensities in subjects with bipolar disorder. Psychiatry Clin. Neurosci. 2004, 58:516-521.
2. Angst J. Bipolar disorder-a seriously underestimated health burden. Eur. Arch. Psychiatry Clin. Neurosci. 2004, 254:59-60.
3. Angst J. Bipolar disorder-methodological problems and future perspectives. Dialogues Clin. Neurosci. 2008, 10:129-139.
4. Angst J., Adolfsson R., Benazzi F., Gamma A., Hantouche E., Meyer T.D., Skeppar P., Vieta E., Scott J. The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients. J. Affect. Disord. 2005, 88:217-233.
5. Angst J., Sellaro R., Stassen H.H., Gamma A. Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions. J. Affect. Disord. 2005, 84:149-157.
6. Angst J., Azorin J.M., Bowden C.L., Perugi G., Vieta E., Gamma A., Young A.H. Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE study. Arch. Gen. Psychiatry 2011, 68:791-798.
7. Angst J., Cui L., Swendsen J., Rothen S., Cravchik A., Kessler R.C., Merikangas K.R. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am. J. Psychiatry 2010, 167:1194-1201.
8. Angst J., Perris C. Zur Nosologie endogener Psychosen. Vergleich der Ergebnisse zweier Untersuchungen. Arch. Psychiatr. Nervenkrankh. 1968, 210:373-386.
9. Aylward E.H., Roberts-Twillie J.V., Barta P.E., Kumar A.J., Harris G.J., Geer M., Peyser C.E., Pearlson G.D. Basal ganglia volumes and white matter hyperintensities in patients with bipolar disorder. Am. J. Psychiatry 1994, 151:687-693.
10. Balanza-Martinez V., Rubio C., Selva-Vera G., Martinez-Aran A., Sanchez-Moreno J., Salazar-Fraile J., Vieta E., Tabares-Seisdedos R. Neurocognitive endophenotypes (endophenocognitypes) from studies of relatives of bipolar disorder subjects: a systematic review. Neurosci. Biobehav. Rev. 2008, 32:1426-1438.
11. Baldessarini R.J., Tondo L., Davis P., Pompili M., Goodwin F.K., Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord. 2006, 8:625-639.
12. Beyer J.L., Young R., Kuchibhatla M., Krishnan K.R. Hyperintense MRI lesions in bipolar disorder: a meta-analysis and review. Int. Rev. Psychiatry 2009, 21:394-409.
13. Bora E., Yucel M., Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J. Affect. Disord. 2009, 113:1-20.
14. Brown R., Taylor M.J., Geddes J. Aripiprazole alone or in combination for acute mania. Cochrane Database Syst. Rev. 2013, 12.
15. Calabrese J.R., Huffman R.F., White R.L., Edwards S., Thompson T.R., Ascher J.A., Monaghan E.T., Leadbetter R.A. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord. 2008, 10:323-333.
16. Casey B.J., Oliveri M.E., Insel T. A neurodevelopmental perspective on the research domain criteria (RDoC) framework. Biol. Psychiatry 2014, 76:350-353.
17. Chandler R.A., Wakeley J., Goodwin G.M., Rogers R.D. Altered risk-aversion and risk-seeking behavior in bipolar disorder. Biol. Psychiatry 2009, 66:840-846.
18. Chen C.H., Lee C.S., Lee M.T., Ouyang W.C., Chen C.C., Chong M.Y., Wu J.Y., Tan H.K., Lee Y.C., Chuo L.J., Chiu N.Y., Tsang H.Y., Chang T.J., Lung F.W., Chiu C.H., Chang C.H., Chen Y.S., Hou Y.M., Lai T.J., Tung C.L., Chen C.Y., Lane H.Y., Su T.P., Feng J., Lin J.J., Chang C.J., Teng P.R., Liu C.Y., Chen C.K., Liu I.C., Chen J.J., Lu T., Fan C.C., Wu C.K., Li C.F., Wang K.H., Wu L.S., Peng H.L., Chang C.P., Lu L.S., Chen Y.T., Cheng A.T. Variant GADL1 and response to lithium therapy in bipolar I disorder. N. Engl. J. Med. 2014, 370:119-128.
19. Chen C.H., Ridler K., Suckling J., Williams S., Fu C.H., Merlo-Pich E., Bullmore E. Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol. Psychiatry 2007, 62:407-414.
20. Chen P., Lin J.J., Lu C.S., Ong C.T., Hsieh P.F., Yang C.C., Tai C.T., Wu S.L., Lu C.H., Hsu Y.C., Yu H.Y., Ro L.S., Lu C.T., Chu C.C., Tsai J.J., Su Y.H., Lan S.H., Sung S.F., Lin S.Y., Chuang H.P., Huang L.C., Chen Y.J., Tsai P.J., Liao H.T., Lin Y.H., Chen C.H., Chung W.H., Hung S.I., Wu J.Y., Chang C.F., Chen L., Chen Y.T., Shen C.Y. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N. Engl. J. Med. 2011, 364:1126-1133.
21. Chiu C.T., Wang Z., Hunsberger J.G., Chuang D.M. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol. Rev. 2013, 65:105-142.
22. Cipriani A., Barbui C., Salanti G., Rendell J., Brown R., Stockton S., Purgato M., Spineli L.M., Goodwin G.M., Geddes J.R. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011, 378:1306-1315.
23. Clausen T., Zauner A., Levasseur J.E., Rice A.C., Bullock R. Induced mitochondrial failure in the feline brain: implications for understanding acute post-traumatic metabolic events. Brain Res. 2001, 908:35-48.
24. Colom F., Vieta E., Daban C., Pacchiarotti I., Sanchez-Moreno J. Clinical and therapeutic implications of predominant polarity in bipolar disorder. J. Affect. Disord. 2006, 93:13-17.
25. Craddock N., Sklar P. Genetics of bipolar disorder. Lancet 2013, 381:1654-1662.
26. Cuthbert B.N. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry 2014, 13:28-35.
27. Delvecchio G., Fossati P., Boyer P., Brambilla P., Falkai P., Gruber O., Hietala J., Lawrie S.M., Martinot J.L., McIntosh A.M., Meisenzahl E., Frangou S. Common and distinct neural correlates of emotional processing in Bipolar Disorder and Major Depressive Disorder: a voxel-based meta-analysis of functional magnetic resonance imaging studies. Eur. Neuropsychopharmacol. 2012, 22:100-113.
28. Dong E., Chen Y., Gavin D.P., Grayson D.R., Guidotti A. Valproate induces DNA demethylation in nuclear extracts from adult mouse brain. Epigenetics 2010, 5:730-735.
29. Dong E., Nelson M., Grayson D.R., Costa E., Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc. Natl. Acad. Sci. USA 2008, 105:13614-13619.
30. Dudek D., Siwek M., Zielinska D., Jaeschke R., Rybakowski J. Diagnostic conversions from major depressive disorder into bipolar disorder in an outpatient setting: results of a retrospective chart review. J. Affect. Disord. 2013, 144:112-115.
31. Ewald H., Wang A.G., Vang M., Mors O., Nyegaard M., Kruse T.A. A haplotype-based study of lithium responding patients with bipolar affective disorder on the Faroe Islands. Psychiatr. Genet. 1999, 9:23-34.
32. Fava G.A., Guidi J., Grandi S., Hasler G. The missing link between clinical states and biomarkers in mental disorders. Psychother. Psychosom. 2014, 83:136-141.
33. Frank E., Kupfer D.J., Thase M.E., Mallinger A.G., Swartz H.A., Fagiolini A.M., Grochocinski V., Houck P., Scott J., Thompson W., Monk T. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch. Gen. Psychiatry 2005, 62:996-1004.
34. Frank E., Swartz H.A., Kupfer D.J. Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol. Psychiatry 2000, 48:593-604.
35. Frey B.N., Andreazza A.C., Houenou J., Jamain S., Goldstein B.I., Frye M.A., Leboyer M., Berk M., Malhi G.S., Lopez-Jaramillo C., Taylor V.H., Dodd S., Frangou S., Hall G.B., Fernandes B.S., Kauer-Sant'Anna M., Yatham L.N., Kapczinski F., Young L.T. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust. N. Z. J. Psychiatry 2013, 47:321-332.
36. Fries G.R., Vasconcelos-Moreno M.P., Gubert C., Santos B.T., da Rosa A.L., Eisele B., Sartori J., Pfaffenseller B., Kapczinski F., Kauer-Sant'anna M. Early apoptosis in peripheral blood mononuclear cells from patients with bipolar disorder. J. Affect. Disord. 2014, 152-154:474-477.
37. Geddes J.R., Burgess S., Hawton K., Jamison K., Goodwin G.M. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am. J. Psychiatry 2004, 161:217-222.
38. Geddes J.R., Calabrese J.R., Goodwin G.M. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br. J. Psychiatry 2009, 194:4-9.
39. Geddes J.R., Miklowitz D.J. Treatment of bipolar disorder. Lancet 2013, 381:1672-1682.
40. Gigante A.D., Bond D.J., Lafer B., Lam R.W., Young L.T., Yatham L.N. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord. 2012, 14:478-487.
41. Glahn D.C., Knowles E.E., McKay D.R., Sprooten E., Raventos H., Blangero J., Gottesman, Almasy L. Arguments for the sake of endophenotypes: examining common misconceptions about the use of endophenotypes in psychiatric genetics. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2014, 165B:122-130.
42. Glimcher P.W., Rustichini A. Neuroeconomics: the consilience of brain and decision. Science 2004, 306:447-452.
43. Golden R.N., Gaynes B.N., Ekstrom R.D., Hamer R.M., Jacobsen F.M., Suppes T., Wisner K.L., Nemeroff C.B. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am. J. Psychiatry 2005, 162:656-662.
44. Gonzalez D., Bienroth M., Curtis V., Debenham M., Jones S., Pitsi D., George M. Consensus statement on the use of intramuscular aripiprazole for the rapid control of agitation in bipolar mania and schizophrenia. Curr. Med. Res. Opin. 2013, 29:241-250.
45. Gottesman, Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 2003, 160:636-645.
46. Gottesman, Shields J. Genetic theorizing and schizophrenia. Br. J. Psychiatry 1973, 122:15-30.
47. Grande I., Magalhaes P.V., Chendo I., Stertz L., Panizutti B., Colpo G.D., Rosa A.R., Gama C.S., Kapczinski F., Vieta E. Staging bipolar disorder: clinical, biochemical, and functional correlates. Acta Psychiatr. Scand. 2014, 129:437-444.
48. Grawe K. Psychological Therapy 2004, Hogrefe Publishing, Göttingen. Revised edition.
49. Greil W., Haberle A., Haueis P., Grohmann R., Russmann S. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J. Affect. Disord. 2012, 136:534-542.
50. Grunze H., Azorin J.M. Clinical decision making in the treatment of mixed states. World J. Biol. Psychiatry 2014, 1-14.
51. Guidotti A., Auta J., Chen Y., Davis J.M., Dong E., Gavin D.P., Grayson D.R., Matrisciano F., Pinna G., Satta R., Sharma R.P., Tremolizzo L., Tueting P. Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology 2011, 60:1007-1016.
52. Hallahan B., Newell J., Soares J.C., Brambilla P., Strakowski S.M., Fleck D.E., Kieseppa T., Altshuler L.L., Fornito A., Malhi G.S., McIntosh A.M., Yurgelun-Todd D.A., Labar K.S., Sharma V., MacQueen G.M., Murray R.M., McDonald C. Structural magnetic resonance imaging in bipolar disorder: an international collaborative mega-analysis of individual adult patient data. Biol. Psychiatry 2011, 69:326-335.
53. Hasler G. Can the neuroeconomics revolution revolutionize psychiatry?. Neurosci. Biobehav. Rev. 2012, 36:64-78.
54. Hasler G., Drevets W.C., Gould T.D., Gottesman II, Manji H.K. Toward constructing an endophenotype strategy for bipolar disorders. Biol. Psychiatry 2006, 60:93-105.
55. Hasler G., Drevets W.C., Manji H.K., Charney D.S. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004, 29:1765-1781.
56. Hasler G., Luckenbaugh D.A., Snow J., Meyers N., Waldeck T., Geraci M., Roiser J., Knutson B., Charney D.S., Drevets W.C. Reward processing after catecholamine depletion in unmedicated, remitted subjects with major depressive disorder. Biol. Psychiatry 2009, 66:201-205.
57. Hasler G., Northoff G. Discovering imaging endophenotypes for major depression. Mol. Psychiatry 2011, 16:604-619.
58. Holtzheimer P.E., Kelley M.E., Gross R.E., Filkowski M.M., Garlow S.J., Barrocas A., Wint D., Craighead M.C., Kozarsky J., Chismar R., Moreines J.L., Mewes K., Posse P.R., Gutman D.A., Mayberg H.S. Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch. Gen. Psychiatry 2012, 69:150-158.
59. Hou L., Heilbronner U., Rietschel M., Kato T., Kuo P.H., McMahon F.J., Schulze T.G. Variant GADL1 and response to lithium in bipolar I disorder. N. Engl. J. Med. 2014, 370:1857-1859.
60. Jimenez E., Arias B., Mitjans M., Goikolea J.M., Roda E., Saiz P.A., Garcia-Portilla M.P., Buron P., Bobes J., Oquendo M.A., Vieta E., Benabarre A. Genetic variability at IMPA2, INPP1 and GSK3beta increases the risk of suicidal behavior in bipolar patients. Eur. Neuropsychopharmacol. 2013, 23:1452-1462.
61. Kapczinski F., Magalhaes P.V., Balanza-Martinez V., Dias V.V., Frangou S., Gama C.S., Gonzalez-Pinto A., Grande I., Ha K., Kauer-Sant'Anna M., Kunz M., Kupka R., Leboyer M., Lopez-Jaramillo C., Post R.M., Rybakowski J.K., Scott J., Strejilevitch S., Tohen M., Vazquez G., Yatham L., Vieta E., Berk M. Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report. Acta Psychiatr Scand. 2015, 150:354-363.
62. Kato T., Fujii K., Kamiya A., Kato N. White matter hyperintensity detected by magnetic resonance imaging and lithium response in bipolar disorder: a preliminary observation. Psychiatry Clin. Neurosci. 2000, 54:117-120.
63. Keener M.T., Phillips M.L. Neuroimaging in bipolar disorder: a critical review of current findings. Curr. Psychiatry Rep. 2007, 9:512-520.
64. Kendler K.S. Reflections on the relationship between psychiatric genetics and psychiatric nosology. Am. J. Psychiatry 2006, 163:1138-1146.
65. Kendler K.S. What psychiatric genetics has taught us about the nature of psychiatric illness and what is left to learn. Mol. Psychiatry 2013, 18:1058-1066.
66. Kerner B. Genetics of bipolar disorder. Appl. Clin. Genet. 2014, 7:33-42.
67. Kieseppa T., Partonen T., Haukka J., Kaprio J., Lonnqvist J. High concordance of bipolar I disorder in a nationwide sample of twins. Am. J. Psychiatry 2004, 161:1814-1821.
68. Kim B., Kim C.Y., Lee M.J., Joo Y.H. Preliminary evidence on the association between XBP1-116C/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders. Psychiatry Res. 2009, 168:209-212.
69. Knutson B., Bhanji J.P., Cooney R.E., Atlas L.Y., Gotlib I.H. Neural responses to monetary incentives in major depression. Biol. Psychiatry 2008, 63:686-692.
70. Kohler S., Gaus S., Bschor T. The challenge of treatment in bipolar depression: evidence from clinical guidelines, treatment recommendations and complex treatment situations. Pharmacopsychiatry 2014, 47:53-59.
71. Kruger S., Trevor Young L., Braunig P. Pharmacotherapy of bipolar mixed states. Bipolar Disord. 2005, 7:205-215.
72. Kunz M., Cereser K.M., Goi P.D., Fries G.R., Teixeira A.L., Fernandes B.S., Belmonte-de-Abreu P.S., Kauer-Sant'Anna M., Kapczinski F., Gama C.S. Serum levels of IL-6, IL-10 and TNF-alpha in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev. Bras. Psiquiatr 2011, 33:268-274.
73. Kwentus J., Riesenberg R.A., Marandi M., Manning R.A., Allen M.H., Fishman R.S., Spyker D.A., Kehne J.H., Cassella J.V. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012, 14:31-40.
74. Lapalme M., Hodgins S., LaRoche C. Children of parents with bipolar disorder: a metaanalysis of risk for mental disorders. Can. J. Psychiatry 1997, 42:623-631.
75. Leboyer M., Soreca I., Scott J., Frye M., Henry C., Tamouza R., Kupfer D.J. Can bipolar disorder be viewed as a multi-system inflammatory disease?. J. Affect. Disord. 2012, 141:1-10.
76. Lee S.H., Wray N.R., Goddard M.E., Visscher P.M. Estimating missing heritability for disease from genome-wide association studies. Am. J. Hum. Genet. 2011, 88:294-305.
77. Licht R.W., Gijsman H., Nolen W.A., Angst J. Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta. Psychiatr. Scand. 2008, 118:337-346.
78. Lim C.S., Baldessarini R.J., Vieta E., Yucel M., Bora E., Sim K. Longitudinal neuroimaging and neuropsychological changes in bipolar disorder patients: review of the evidence. Neurosci. Biobehav. Rev. 2013, 37:418-435.
79. MacCabe J.H., Lambe M.P., Cnattingius S., Sham P.C., David A.S., Reichenberg A., Murray R.M., Hultman C.M. Excellent school performance at age 16 and risk of adult bipolar disorder: national cohort study. Br. J. Psychiatry 2010, 196:109-115.
80. Machado-Vieira R., Soeiro-De-Souza M.G., Richards E.M., Teixeira A.L., Zarate C.A. Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach. World J. Biol. Psychiatry 2014, 15:84-95.
81. Marlinge E., Bellivier F., Houenou J. White matter alterations in bipolar disorder: potential for drug discovery and development. Bipolar Disord. 2014, 16:97-112.
82. Mayberg H.S., Brannan S.K., Mahurin R.K., Jerabek P.A., Brickman J.S., Tekell J.L., Silva J.A., McGinnis S., Glass T.G., Martin C.C., Fox P.T. Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997, 8:1057-1061.
83. Mayberg H.S., Lozano A.M., Voon V., McNeely H.E., Seminowicz D., Hamani C., Schwalb J.M., Kennedy S.H. Deep brain stimulation for treatment-resistant depression. Neuron 2005, 45:651-660.
84. McDonald C., Bullmore E.T., Sham P.C., Chitnis X., Wickham H., Bramon E., Murray R.M. Association of genetic risks for schizophrenia and bipolar disorder with specific and generic brain structural endophenotypes. Arch. Gen. Psychiatry 2004, 61:974-984.
85. McElroy S.L., Weisler R.H., Chang W., Olausson B., Paulsson B., Brecher M., Agambaram V., Merideth C., Nordenhem A., Young A.H. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J. Clin. Psychiatry 2010, 71:163-174.
86. McGuffin P., Rijsdijk F., Andrew M., Sham P., Katz R., Cardno A. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch. Gen. Psychiatry 2003, 60:497-502.
87. McIntyre R.S., Cohen M., Zhao J., Alphs L., Macek T.A., Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009, 11:673-686.
88. Miklowitz D.J. A review of evidence-based psychosocial interventions for bipolar disorder. J. Clin. Psychiatry 2006, 67(Suppl. 11):28-33.
89. Moore G.J., Cortese B.M., Glitz D.A., Zajac-Benitez C., Quiroz J.A., Uhde T.W., Drevets W.C., Manji H.K. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J. Clin. Psychiatry 2009, 70:699-705.
90. Morris S.E., Cuthbert B.N. Research Domain Criteria: cognitive systems, neural circuits, and dimensions of behavior. Dialogues Clin. Neurosci. 2012, 14:29-37.
91. Muhleisen T.W., Leber M., Schulze T.G., Strohmaier J., Degenhardt F., Treutlein J., Mattheisen M., Forstner A.J., Schumacher J., Breuer R., Meier S., Herms S., Hoffmann P., Lacour A., Witt S.H., Reif A., Muller-Myhsok B., Lucae S., Maier W., Schwarz M., Vedder H., Kammerer-Ciernioch J., Pfennig A., Bauer M., Hautzinger M., Moebus S., Priebe L., Czerski P.M., Hauser J., Lissowska J., Szeszenia-Dabrowska N., Brennan P., McKay J.D., Wright A., Mitchell P.B., Fullerton J.M., Schofield P.R., Montgomery G.W., Medland S.E., Gordon S.D., Martin N.G., Krasnow V., Chuchalin A., Babadjanova G., Pantelejeva G., Abramova L.I., Tiganov A.S., Polonikov A., Khusnutdinova E., Alda M., Grof P., Rouleau G.A., Turecki G., Laprise C., Rivas F., Mayoral F., Kogevinas M., Grigoroiu-Serbanescu M., Propping P., Becker T., Rietschel M., Nothen M.M., Cichon S. Genome-wide association study reveals two new risk loci for bipolar disorder. Nat. Commun. 2014, 5:3339.
92. Munakata K., Iwamoto K., Bundo M., Kato T. Mitochondrial DNA 3243A>G mutation and increased expression of LARS2 gene in the brains of patients with bipolar disorder and schizophrenia. Biol. Psychiatry 2005, 57:525-532.
93. Nivoli A.M., Colom F., Murru A., Pacchiarotti I., Castro-Loli P., Gonzalez-Pinto A., Fountoulakis K.N., Vieta E. New treatment guidelines for acute bipolar depression: a systematic review. J. Affect. Disord. 2011, 129:14-26.
94. Nugent A.C., Milham M.P., Bain E.E., Mah L., Cannon D.M., Marrett S., Zarate C.A., Pine D.S., Price J.L., Drevets W.C. Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry. Neuroimage 2006, 30:485-497.
95. Pacchiarotti I., Bond D.J., Baldessarini R.J., Nolen W.A., Grunze H., Licht R.W., Post R.M., Berk M., Goodwin G.M., Sachs G.S., Tondo L., Findling R.L., Youngstrom E.A., Tohen M., Undurraga J., Gonzalez-Pinto A., Goldberg J.F., Yildiz A., Altshuler L.L., Calabrese J.R., Mitchell P.B., Thase M.E., Koukopoulos A., Colom F., Frye M.A., Malhi G.S., Fountoulakis K.N., Vazquez G., Perlis R.H., Ketter T.A., Cassidy F., Akiskal H., Azorin J.M., Valenti M., Mazzei D.H., Lafer B., Kato T., Mazzarini L., Martinez-Aran A., Parker G., Souery D., Ozerdem A., McElroy S.L., Girardi P., Bauer M., Yatham L.N., Zarate C.A., Nierenberg A.A., Birmaher B., Kanba S., El-Mallakh R.S., Serretti A., Rihmer Z., Young A.H., Kotzalidis G.D., MacQueen G.M., Bowden C.L., Ghaemi S.N., Lopez-Jaramillo C., Rybakowski J., Ha K., Perugi G., Kasper S., Amsterdam J.D., Hirschfeld R.M., Kapczinski F., Vieta E. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am. J. Psychiatry 2013, 170:1249-1262.
96. Pacchiarotti I., Valenti M., Bonnin C.M., Rosa A.R., Murru A., Kotzalidis G.D., Nivoli A.M., Sanchez-Moreno J., Vieta E., Colom F. Factors associated with initial treatment response with antidepressants in bipolar disorder. Eur. Neuropsychopharmacol. 2011, 21:362-369.
97. Pena C.J., Bagot R.C., Labonte B., Nestler E.J. Epigenetic signaling in psychiatric disorders. J. Mol. Biol. 2015, (in press).
98. Perlis R.H. Translating biomarkers to clinical practice. Mol. Psychiatry 2011, 16:1076-1087.
99. Perlis R.H., Smoller J.W., Ferreira M.A., McQuillin A., Bass N., Lawrence J., Sachs G.S., Nimgaonkar V., Scolnick E.M., Gurling H., Sklar P., Purcell S. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am. J. Psychiatry 2009, 166:718-725.
100. Perlis R.H., Uher R., Ostacher M., Goldberg J.F., Trivedi M.H., Rush A.J., Fava M. Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch. Gen. Psychiatry 2011, 68:351-360.
101. Pizzagalli D.A., Holmes A.J., Dillon D.G., Goetz E.L., Birk J.L., Bogdan R., Dougherty D.D., Iosifescu D.V., Rauch S.L., Fava M. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am. J. Psychiatry 2009, 166:702-710.
102. Popovic D., Reinares M., Goikolea J.M., Bonnin C.M., Gonzalez-Pinto A., Vieta E. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur. Neuropsychopharmacol. 2012, 22:339-346.
103. Popovic D., Reinares M., Scott J., Nivoli A., Murru A., Pacchiarotti I., Vieta E., Colom F. Polarity index of psychological interventions in maintenance treatment of bipolar disorder. Psychother. Psychosom. 2013, 82:292-298.
104. Rangel A., Camerer C., Montague P.R. A framework for studying the neurobiology of value-based decision making. Nat. Rev. Neurosci. 2008, 9:545-556.
105. Reinares M., Sanchez-Moreno J., Fountoulakis K.N. Psychosocial interventions in bipolar disorder: what, for whom, and when. J. Affect. Disord. 2014, 156:46-55.
106. Robins E., Guze S.B. Establishment of diagnostic validity in psychiatrc illness: its application to schizophrenia. Am. J. Psychiatry 1970, 126:983-987.
107. Salehi B., Preuss N., van der Veen J.W., Shen J., Neumeister A., Drevets W.C., Hodgkinson C., Goldman D., Wendland J.R., Singleton A., Gibbs J.R., Cookson M.R., Hasler G. Age-modulated association between prefrontal NAA and the BDNF gene. Int. J. Neuropsychopharmacol. 2013, 16:1185-1193.
108. Salvadore G., van der Veen J.W., Zhang Y., Marenco S., Machado-Vieira R., Baumann J., Ibrahim L.A., Luckenbaugh D.A., Shen J., Drevets W.C., Zarate C.A. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int. J. Neuropsychopharmacol. 2012, 15:1063-1072.
109. Samalin L., Guillaume S., Courtet P., Abbar M., Lancrenon S., Llorca P.M. Methodological differences between pharmacological treatment guidelines for bipolar disorder: what to do for the clinicians?. Compr. Psychiatry 2013, 54:309-320.
110. Schultz W. Behavioral theories and the neurophysiology of reward. Annu. Rev. Psychol. 2006, 57:87-115.
111. Schumann G., Binder E.B., Holte A., de Kloet E.R., Oedegaard K.J., Robbins T.W., Walker-Tilley T.R., Bitter I., Brown V.J., Buitelaar J., Ciccocioppo R., Cools R., Escera C., Fleischhacker W., Flor H., Frith C.D., Heinz A., Johnsen E., Kirschbaum C., Klingberg T., Lesch K.P., Lewis S., Maier W., Mann K., Martinot J.L., Meyer-Lindenberg A., Muller C.P., Muller W.E., Nutt D.J., Persico A., Perugi G., Pessiglione M., Preuss U.W., Roiser J.P., Rossini P.M., Rybakowski J.K., Sandi C., Stephan K.E., Undurraga J., Vieta E., van der Wee N., Wykes T., Haro J.M., Wittchen H.U. Stratified medicine for mental disorders. Eur. Neuropsychopharmacol. 2014, 24:5-50.
112. Serretti A., Artioli P., Lorenzi C., Pirovano A., Tubazio V., Zanardi R. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int. J. Neuropsychopharmacol. 2004, 7:453-460.
113. Severino G., Squassina A., Costa M., Pisanu C., Calza S., Alda M., Del Zompo M., Manchia M. Pharmacogenomics of bipolar disorder. Pharmacogenomics 2013, 14:655-674.
114. Simpson S.G., McMahon F.J., McInnis M.G., MacKinnon D.F., Edwin D., Folstein S.E., DePaulo J.R. Diagnostic reliability of bipolar II disorder. Arch. Gen. Psychiatry 2002, 59:736-740.
115. Snitz B.E., Macdonald A.W., Carter C.S. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr. Bull. 2006, 32:179-194.
116. Snyder J.S., Soumier A., Brewer M., Pickel J., Cameron H.A. Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature 2011, 476:458-461.
117. Sole B., Bonnin C.M., Mayoral M., Amann B.L., Torres I., Gonzalez-Pinto A., Jimenez E., Crespo J.M., Colom F., Tabares-Seisdedos R., Reinares M., Ayuso-Mateos J.L., Soria S., Garcia-Portilla M.P., Ibanez A., Vieta E., Martinez-Aran A., Torrent C. Functional remediation for patients with bipolar II disorder: improvement of functioning and subsyndromal symptoms. Eur. Neuropsychopharmacol. 2015, the C.F.R.G., (in press).
118. Stork C., Renshaw P.F. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol. Psychiatry 2005, 10:900-919.
119. Stoy M., Schlagenhauf F., Sterzer P., Bermpohl F., Hagele C., Suchotzki K., Schmack K., Wrase J., Ricken R., Knutson B., Adli M., Bauer M., Heinz A., Strohle A. Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram. J. Psychopharmacol. 2012, 26:677-688.
120. Sullivan P.F., Daly M.J., O'Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat. Rev. Genet. 2012, 13:537-551.
121. Swartz H.A., Fagiolini A. Cardiovascular disease and bipolar disorder: risk and clinical implications. J. Clin. Psychiatry 2012, 73:1563-1565.
122. Taylor V., MacQueen G. Associations between bipolar disorder and metabolic syndrome: a review. J. Clin. Psychiatry 2006, 67:1034-1041.
123. Torrent C., Del Mar Bonnin C., Martinez-Aran A., Valle J., Amann B.L., Gonzalez-Pinto A., Crespo J.M., Ibanez A., Garcia-Portilla M.P., Tabares-Seisdedos R., Arango C., Colom F., Sole B., Pacchiarotti I., Rosa A.R., Ayuso-Mateos J.L., Anaya C., Fernandez P., Landin-Romero R., Alonso-Lana S., Ortiz-Gil J., Segura B., Barbeito S., Vega P., Fernandez M., Ugarte A., Subira M., Cerrillo E., Custal N., Menchon J.M., Saiz-Ruiz J., Rodao J.M., Isella S., Alegria A., Al-Halabi S., Bobes J., Galvan G., Saiz P.A., Balanza-Martinez V., Selva G., Fuentes-Dura I., Correa P., Mayoral M., Chiclana G., Merchan-Naranjo J., Rapado-Castro M., Salamero M., Vieta E. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am J. Psychiatry 2013, 170(8):852-859. 10.1176/appi.ajp.2012.12070971.
124. Turecki G., Grof P., Grof E., D'Souza V., Lebuis L., Marineau C., Cavazzoni P., Duffy A., Betard C., Zvolsky P., Robertson C., Brewer C., Hudson T.J., Rouleau G.A., Alda M. Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol. Psychiatry 2001, 6:570-578.
125. Vargas C., Lopez-Jaramillo C., Vieta E. A systematic literature review of resting state network-functional MRI in bipolar disorder. J. Affect. Disord. 2013, 150:727-735.
126. Vieta E. The bipolar maze: a roadmap through translational psychopathology. Acta Psychiatr. Scand. 2014, 129:323-327.
127. Wang Z., Li Z., Chen J., Huang J., Yuan C., Hong W., Yu S., Fang Y. Association of BDNF gene polymorphism with bipolar disorders in Han Chinese population. Genes Brain Behav. 2012, 11:524-528.
128. Whalley H.C., Sprooten E., Hackett S., Hall L., Blackwood D.H., Glahn D.C., Bastin M., Hall J., Lawrie S.M., Sussmann J.E., McIntosh A.M. Polygenic risk and white matter integrity in individuals at high risk of mood disorder. Biol. Psychiatry 2013, 74(4):280-286. 10.1016/j.biopsych.2013.01.027.
129. Xiao Y., Camarillo C., Ping Y., Arana T.B., Zhao H., Thompson P.M., Xu C., Su B.B., Fan H., Ordonez J., Wang L., Mao C., Zhang Y., Cruz D., Escamilla M.A., Li X. The DNA methylome and transcriptome of different brain regions in schizophrenia and bipolar disorder. PLoS One 2014, 9:e95875.
130. Yeo R.A., Gangestad S.W., Walton E., Ehrlich S., Pommy J., Turner J.A., Liu J., Mayer A.R., Schulz S.C., Ho B.C., Bustillo J.R., Wassink T.H., Sponheim S.R., Morrow E.M., Calhoun V.D. Genetic influences on cognitive endophenotypes in schizophrenia. Schizophr. Res. 2014, 156:71-75.
131. Zanardi R., Serretti A., Rossini D., Franchini L., Cusin C., Lattuada E., Dotoli D., Smeraldi E. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol. Psychiatry 2001, 50:323-330.
132. Zimmermann P., Bruckl T., Nocon A., Pfister H., Lieb R., Wittchen H.U., Holsboer F., Angst J. Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bipolarity. Arch. Gen. Psychiatry 2009, 66:1341-1352.